CL2004000647A1 - Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am - Google Patents

Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Info

Publication number
CL2004000647A1
CL2004000647A1 CL200400647A CL2004000647A CL2004000647A1 CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1 CL 200400647 A CL200400647 A CL 200400647A CL 2004000647 A CL2004000647 A CL 2004000647A CL 2004000647 A1 CL2004000647 A1 CL 2004000647A1
Authority
CL
Chile
Prior art keywords
inhibitors
amiloid
beta
angiopatia
heterocicles
Prior art date
Application number
CL200400647A
Other languages
English (en)
Inventor
Anthony Frank Resnick Ly Kreft
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2004000647A1 publication Critical patent/CL2004000647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON COMPUESTOS FLUORO Y TRIFLUOROALQUILO QUE CONTIENEN INHIBIDORES DE SULFONAMIDAS HETEROCICLICOCS DE BETA AMILOIDES SU METODO DE PRODUCCION Y SUS DERIVADOS DE LOS MISMOS Y LOS METODOS DE TRATAMIENTOS QUE LOS EMPLEAN. PARTICULARMENTE, LOS INHIBIDORES UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.
CL200400647A 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am CL2004000647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31

Publications (1)

Publication Number Publication Date
CL2004000647A1 true CL2004000647A1 (es) 2005-02-04

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400647A CL2004000647A1 (es) 2003-03-31 2004-03-26 Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am

Country Status (22)

Country Link
US (3) US7300951B2 (es)
EP (1) EP1608638A1 (es)
JP (1) JP2006522126A (es)
KR (1) KR20060002908A (es)
CN (2) CN1780829B (es)
AR (1) AR043940A1 (es)
AU (1) AU2004230844B2 (es)
BR (1) BRPI0408962A (es)
CA (1) CA2517155A1 (es)
CL (1) CL2004000647A1 (es)
CO (1) CO5640049A2 (es)
CR (1) CR7951A (es)
EC (1) ECSP056128A (es)
MX (1) MXPA05010368A (es)
NO (1) NO20054263L (es)
NZ (1) NZ542468A (es)
RU (1) RU2342374C2 (es)
SG (1) SG167669A1 (es)
TW (1) TWI336698B (es)
UA (1) UA82093C2 (es)
WO (1) WO2004092155A1 (es)
ZA (1) ZA200507896B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267853T3 (es) * 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
ES2325205T3 (es) * 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
KR20050010882A (ko) * 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
UA82093C2 (uk) * 2003-03-31 2008-03-11 Уайт Фтор- та трифторалкіловмісні гетероциклічні сульфонамідні інгібітори утворення бета-амілоїду та їх похідні
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
EP1984347A1 (en) * 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
AR059518A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
CA2649396A1 (en) 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
EP2073827A4 (en) * 2006-11-03 2012-04-25 Univ Northwestern THERAPY FOR MULTIPLE SCLEROSIS
WO2009012205A1 (en) * 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
PA8789601A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Proceso para la preparación de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterocíclicas
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2009089237A1 (en) * 2008-01-11 2009-07-16 Wyeth Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as beta-amyloid inhibitors
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
EP2334620B1 (en) 2008-09-05 2018-09-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
US9223217B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
CA2792613C (en) * 2010-03-10 2016-06-28 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2017200762A2 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0510700A3 (en) 1991-04-26 1992-12-16 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) * 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
DE69637307T2 (de) * 1995-11-28 2008-02-28 Cephalon, Inc. Aus d-aminosäuren abgeleitete cystein-und serinproteasehemmer
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
HUP0001383A3 (en) 1996-11-22 2001-11-28 Lilly Co Eli N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use
DE19650196A1 (de) * 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
US6495578B1 (en) 1999-04-19 2002-12-17 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
WO2001027108A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
CA2404125C (en) 2000-03-20 2011-01-25 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
ES2267853T3 (es) * 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
US6657070B2 (en) * 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
EP1461332A4 (en) 2001-12-11 2009-10-21 Wyeth Corp PRODUCTION OF ALPHA-AMINO ACIDS AND CHIRALLY PURE ALPHA-AMINO N-SULFONYL ACIDS
RU2332397C2 (ru) * 2001-12-11 2008-08-27 Уайт Способ синтеза хирально чистых бета-аминоспиртов
KR20050010882A (ko) 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
UA82093C2 (uk) 2003-03-31 2008-03-11 Уайт Фтор- та трифторалкіловмісні гетероциклічні сульфонамідні інгібітори утворення бета-амілоїду та їх похідні
CA2552558A1 (en) 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
AR059518A1 (es) 2006-02-17 2008-04-09 Wyeth Corp Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
EP1984347A1 (en) 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
US7550629B2 (en) 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
CA2649396A1 (en) 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US7476762B2 (en) 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
WO2009012205A1 (en) 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
PA8789801A1 (es) 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
PA8789601A1 (es) 2007-07-16 2009-02-09 Wyeth Corp Proceso para la preparación de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterocíclicas

Also Published As

Publication number Publication date
MXPA05010368A (es) 2005-11-17
NZ542468A (en) 2009-01-31
ECSP056128A (es) 2006-03-01
KR20060002908A (ko) 2006-01-09
RU2342374C2 (ru) 2008-12-27
US20090227667A1 (en) 2009-09-10
CO5640049A2 (es) 2006-05-31
AR043940A1 (es) 2005-08-17
CN101274926A (zh) 2008-10-01
BRPI0408962A (pt) 2006-04-04
TWI336698B (en) 2011-02-01
NO20054263D0 (no) 2005-09-15
US7547725B2 (en) 2009-06-16
ZA200507896B (en) 2007-03-28
AU2004230844A1 (en) 2004-10-28
CA2517155A1 (en) 2004-10-28
UA82093C2 (uk) 2008-03-11
US20070254929A1 (en) 2007-11-01
US20040198778A1 (en) 2004-10-07
SG167669A1 (en) 2011-01-28
EP1608638A1 (en) 2005-12-28
US7300951B2 (en) 2007-11-27
NO20054263L (no) 2005-12-14
CR7951A (es) 2008-10-29
AU2004230844B2 (en) 2010-12-09
WO2004092155A1 (en) 2004-10-28
US7858658B2 (en) 2010-12-28
RU2005133434A (ru) 2006-07-10
JP2006522126A (ja) 2006-09-28
CN1780829B (zh) 2010-12-29
CN1780829A (zh) 2006-05-31
TW200504047A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
GT200500237A (es) Derivados de pirimidina
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso